Introduction {#s1}
============

Cancer is recognized as the leading cause of death in economically developed countries and the second leading cause of death in developing countries. It has been estimated that approximately 12.7 million cancer cases and 7.6 million cancer deaths have been occurred in 2008. Lung cancer was the most commonly diagnosed type of cancer as well as the leading cause of cancer death in males in 2008. Globally, lung cancer accounts for 13% (1.6 million) of the total cases and 18% (1.4 million) of the deaths [@pone.0035970-Jemal1]. Cigarette smoking is the well known risk factor for lung cancer, which accounts for 80% of the worldwide lung cancer burden in males and at least 50% of the burden in females [@pone.0035970-Ezzati1]. Tobacco smoke contains multiple carcinogens that are known to chemically modify of genomic DNA [@pone.0035970-Hecht1] and further lead to genetic mutations [@pone.0035970-Livneh1].

DNA repair genes play a crucial role in maintaining the stability and integrity of genomic DNA. In humans, more than 130 genes are involved in the five major DNA repair pathways, one of which is base excision repair (BER) pathway [@pone.0035970-Wood1]. The BER pathway repairs lesions involving modifications to the DNA bases, including lesions generated by reactive oxygen species. The specificity of BER is supported by DNA glycosylases, which have precise substrate specificities. In mammalian cells there are four major DNA glycosylases including oxoguanine DNA glycosylase (OGG1), which primarily recognizes 8-oxodG but also active on other oxidized purines [@pone.0035970-Scharer1].

The 8-oxoguanine DNA glycosylase (*OGG1*) gene, located at chromosome 3p26.2, encodes the enzyme responsible for the excision of 8-oxoguanine, a mutagenic base byproduct which occurs as a result of exposure to reactive oxygen species. It catalyzes the cleavage of the glycosylic bond between the modified base and the sugar moiety, leaving an abasic apurinic/apyrimidinic site in DNA; the resulting site is then incised, followed by completing of repair with successive actions of a phosphodiesterase, a DNA polymerase and a DNA ligase [@pone.0035970-Dianov1], [@pone.0035970-Karahalil1]. The *OGG1* is highly polymorphic, and a number of single nucleotide polymorphisms (SNPs) have been identified [@pone.0035970-Li1]--[@pone.0035970-Hill1], with at least 231 reported SNPs in the gene region (<http://www.ncbi.nlm.nih.gov/projects/SNP>). However, only few of these reported SNPs are potentially functional and been studied for their associations with cancer susceptibility. For *OGG1*, there are twenty five SNPs that reportedly change amino acid of the protein but only Ser326Cys (rs1052133) was extensively investigated for its association with cancer risk, in particular for lung cancer. Because the results from these studies were inconsistent [@pone.0035970-Li1], [@pone.0035970-Karahalil2]--[@pone.0035970-Kohno1], we performed a meta-analysis of the published reports to further evaluate the association of *OGG1* Ser326Cys SNPs with the risk of lung cancer.

Materials and Methods {#s2}
=====================

Identification and eligibility of relevant studies {#s2a}
--------------------------------------------------

Studies included in this meta-analysis were to meet the following criteria: (a) evaluating the association between *OGG1* Ser326Cys and cancer risk, (b) using a case-control design, (c) providing sufficient information to estimate odds ratios (ORs) and their 95% confidence intervals (CIs).

We searched the electronic literature MEDLINE and EMBASE databases for all relevant articles using the search terms: "*OGG1*, *HMMH*, *MUTM*, *OGH1* or *hOGG1*", "variant or variation or polymorphism" and "lung cancer" (last search was updated on Nov 30, 2011). All eligible studies were retrieved, and their bibliographies were manually checked for other relevant publications. Review articles and bibliographies of other relevant studies identified were hand-searched as well to search for additional eligible studies. Only published studies with full-text articles in English were included. If more than one article was published using the same patient population, only the latest or the largest study would be used in this meta-analysis. Two authors (Wei-Xun Duan and Rui-Xi Hua) independently assessed the articles for compliance with the inclusion criteria, and any disagreement was resolved by discussions till consensus was reached. In addition, investigations departure from Hardy-Weinberg equilibrium (HWE) was excluded from the final analysis.

Data extraction {#s2b}
---------------

The following information was collected from each study: first author\'s surname, year of publication, ethnicity of the study population, cancer types, histological types, source used for controls, total number of cases and controls, genotype methods and numbers of cases and controls with the Ser/Ser, Ser/Cys, and Cys/Cys genotypes for *OGG1*. For those studies that included subjects of different ethnic groups, genotypes data were extracted separately for each of ethnic groups, categorized as Caucasians, Asians, Africans or Mixed which contained more than one ethnic group.

Genotype and gene expression correlation analysis {#s2c}
-------------------------------------------------

The data on *OGG1* Ser326Cys (rs1052133C\>G) genotype and transcript (mRNA) expression levels were available by SNPexp online tool (<http://app3.titan.uio.no/biotools/help.php?app=snpexp>) [@pone.0035970-Holm1]. The genotyping data for *OGG1* were derived from the HapMap phase II release 23 data set consisting of 3.96 million SNP genotypes from 270 individuals from four populations (CEU: 90 Utah residents with ancestry from northern and western Europe; CHB: 45 unrelated Han Chinese in Beijing; JPT: 45 unrelated Japanese in Tokyo; YRI: 90 Yoruba in Ibadan, Nigeria) [@pone.0035970-International1]. The transcript (mRNA) expression data were detected by using genome-wide expression arrays (47294 transcripts) from EBV-transformed lymphoblastoid cell lines from the same 270 individuals [@pone.0035970-Stranger1].

Statistical methods {#s2d}
-------------------

The strength of association between *OGG1* Ser326Cys and lung cancer risk was assessed by calculating ORs with the corresponding 95% CIs. For *OGG1* Ser326Cys, the pooled ORs were also performed for additive (Ser/Ser vs. Cys/Cys and Ser/Cys vs. Cys/Cys), recessive model (Ser/Ser+Ser/Cys vs. Cys/Cys), and dominant model (Ser/Ser vs. Ser/Cys+Cys/Cys). The homogeneity assumption was verified by Chi square-based Q-test. If the studies were found to be homogeneous (with *P*\>0.10 for the Q test), the pooled OR estimate of all studies would be calculated by the fixed-effects model (the Mantel--Haenszel method) [@pone.0035970-Mantel1]. If homogeneity could not be assumed, a random-effects model (the DerSimonian and Laird method) would be used [@pone.0035970-DerSimonian1]. Subgroup analyses were performed by cancer type, ethnicity, study design and sample size. To verify the potential publication bias, a standard error of log (OR) for each study was plotted against its log (OR). Funnel plot asymmetry was assessed by Egger\'s linear regression test [@pone.0035970-Egger1]. To assess the effect of individual studies on the overall risk of cancers, sensitivity analyses were performed by excluding each study individually and recalculating the ORs and the 95% CIs. The mRNA expression levels between two strata were assessed by using Student\'s t test. The transcript expression level trends by genotypes were evaluated by using General linear model. This meta-analysis was performed by using the software STATA version 11.0 (Stata Corporation, College Station, TX) and SAS software (version 9.1; SAS Institute, Cary, NC). All the *P* values were two-sided, and a *P*\<0.05 was considered statistically significant.

Results {#s3}
=======

Study characteristics {#s3a}
---------------------

As shown in [Figure 1](#pone-0035970-g001){ref-type="fig"}, a total of 76 published records were retrieved, of which 45 were excluded after the abstract was found to be irrelevant, and one paper was excluded since they published in Korean [@pone.0035970-Lee1]. A total of 30 case-control studies met the inclusion criteria [@pone.0035970-Li1], [@pone.0035970-Karahalil2]--[@pone.0035970-Kohno1], [@pone.0035970-Bonner1] and were included in the meta-analysis ([Table 1](#pone-0035970-t001){ref-type="table"}). The study by Bonner et al. [@pone.0035970-Bonner1] was excluded in the final analysis because they used the same samples as a previous article [@pone.0035970-Lan1]. The distribution of genotypes for the *OGG1* polymorphism in the controls of all studies was consistent with that expected from the HWE, except for three studies [@pone.0035970-Liu1], [@pone.0035970-Liang1], [@pone.0035970-Zienolddiny1]. Chang et al. [@pone.0035970-Chang1] evaluate the differences in genetic contribution to lung cancer risk in Latinos and African-American ethnic groups, so this study was separated in two. Overall, 27 studies with 9663 cases and 11348 controls investigating the *OGG1* Ser326Cys SNP were included in this meta-analysis. The study of Klinchid et al. [@pone.0035970-Klinchid1] was included only in the calculation of the dominant model, because the genotype distribution was not presented in sufficient detail. Of the 27 studies, sample sizes ranged from 45 to 2155, in which eight studies focused on non-small cell lung cancer (NSCLC) and nineteen on mixed lung cancers. There were eleven studies on Caucasians, twelve studies on Asians, two studies on Africans and two on mixed ethnicity. Almost all of the cases were histologically confirmed. Controls were mainly matched for sex and age. Of all the studies, twelve were population-based, fifteen were hospital-based; three studies with sample size less than 100, nineteen studies with sample size between 100 to 500, and five studies with sample size more than 500. For available histological types, six studies with small cell lung cancer (SCLC), seven with squamous cell carcinoma (SCC), ten with adenocarcinoma (ADC), one with large cell carcinoma (LCC), six with NSCLC thus histological type details not available, and twelve with lung cancer but details not available that were considered as mixed.

![Flow chart of Included Studies.](pone.0035970.g001){#pone-0035970-g001}
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###### Characteristics of studies included in the meta-analysis.

![](pone.0035970.t001){#pone-0035970-t001-1}

  Surname        Year   Country    Ethnicity   Cancer type   Cases/controls   Control source   Genotype method   MAF       H-W
  ------------- ------ ---------- ----------- ------------- ---------------- ---------------- ----------------- ------ -----------
  Khono          1998    Japan       Asian        Mixed          45/42              PB            PCR-SSCP       0.40     0.939
  Sugimura       1999    Japan       Mixed        Mixed         241/197             HB            PCR-SSCP       0.41     0.082
  Wikman         2000   Germany    Caucasian      NSCLC         105/105             HB            PCR-RFLP       0.22     0.067
  Ito            2002    Japan       Asian         ADC          138/240             HB            PCR-CTPP       0.47     0.837
  Le             2002     USA        Mixed        Mixed         298/405             PB            PCR-RFLP       0.35     0.350
  Sunaga         2002    Japan       Asian         ADC          198/152             HB            PCR-RFLP       0.45     0.126
  Lan            2004    China       Asian        Mixed         118/109             PB             SNP500        0.33     0.232
  Park           2004     USA      Caucasian      Mixed         179/350             HB            PCR-RFLP       0.15     0.857
  Vogel          2004   Denmark    Caucasian      Mixed         256/269             PB          real-time PCR    0.24     0.237
  Hung           2005   European   Caucasian    SCC, ADC       2155/2163            HB             TaqMan        0.20     0.215
  Khono          2006    Japan       Asian         ADC          1097/394            HB         pyrosequencing    0.45     0.627
  Loft           2006   Denmark    Caucasian      Mixed         251/261             PB          real-time PCR    0.24     0.200
  Sorensen       2006   Denmark    Caucasian      Mixed         431/796             PB          real-time PCR    0.22     0.258
  Matullo        2006   European   Caucasian      Mixed         116/1094            PB              DHPLC        0.22     0.901
  De Ruyck       2007   Belgium    Caucasian      Mixed         110/110             HB            PCR-RFLP       0.25     0.176
  Hatt           2008   Denmark    Caucasian      Mixed         158/164             PB             TaqMan        0.25     0.536
  Karahalil      2008    Turkey    Caucasian      Mixed         165/250             PB            PCR-RFLP       0.33     0.546
  Chang          2009    Taiwan      Asian        Mixed         1096/997            HB            MassARRAY      0.60     0.741
  Miyaishi       2009    Japan       Asian        Mixed         108/121             HB            PCR-RFLP       0.45     0.271
  Okasaka        2009    Japan       Asian        Mixed         515/1030            PB             TaqMan        0.49     0.070
  Chang          2009     USA       African       Mixed         112/296             PB            Illumina       0.32     0.691
  Chang          2009     USA       African       Mixed         254/280             PB            Illumina       0.15     0.521
  Klinchid       2009   Thailand     Asian        NSCLC          76/75              HB            diASA-AMP            
  Janik          2011    Poland    Caucasian      NSCLC          88/79              HB            PCR-MSSCP      0.15     0.542
  Kohno          2011    Japan       Asian         SCC          377/325             HB         pyrosequencing    0.45     0.704
  Li             2011    China       Asian        Mixed         395/443             HB            PCR-CTPP       0.62     0.329
  Qian           2011    China       Asian        NSCLC         581/601             HB             TaqMan        0.55     0.592
  Liang          2005    China       Asian      SCC, ADC        227/227             HB            diASA-AMP      0.61   **0.043**
  Zienolddiny    2006    Norway    Caucasian      NSCLC         326/386             PB              APEX         0.35   **0.000**
  Liu            2010    Taiwan      Asian        Mixed         358/716             HB            PCR-RFLP       0.64   **0.004**

HB, Hospital based; PB, Population based; SCC, Squamous Cell Carcinoma; NSCLC, non-small cell lung cancer; ADC, Adenocarcinoma; PCR-SSCP, PCR-single strand conformation polymorphism; PCR-RFLP, PCR-restriction fragment length polymorphisms; PCR-CTPP, polymerase chain reaction with confronting two-pair primers; diASA-AMP, di-allele-specific amplification with artificially modified primers; DHPLC, denaturing high performance liquid chromatography.

Meta-analysis results {#s3b}
---------------------

The overall results suggested there was no significant association between *OGG1* Ser326Cys and risk of lung cancer (Ser/Ser vs. Cys/Cys: OR = 1.15, 95% CI = 0.98--1.36; Ser/Cys vs. Cys/Cys: OR = 1.09, 95% CI = 0.95--1.25), recessive (OR = 1.11, 95% CI = 0.97--1.28) or dominant model (OR = 1.09, 95% CI = 0.98--1.21) ([Table 2](#pone-0035970-t002){ref-type="table"}). In the subgroup analysis by sample size, a statistically significant association was found for studies with large sample size (Ser/Ser vs. Cys/Cys: OR = 1.29, 95% CI = 1.13--1.48; Ser/Ser+Ser/Cys vs. Cys/Cys: OR = 1.19, 95% CI = 1.07--1.32), and a relative small sample size (\<100) for dominant model (OR = 1.79, 95% CI = 1.08--2.98) which just included three studies. Further stratification by cancer type, ethnicity, and source of controls all yielded no statistically significant estimates. In the histological type subgroup analysis with more details, the *OGG1* Ser326Cys allele was significantly associated with risk of ADC (Ser/Ser vs. Cys/Cys: OR = 1.32, 95% CI = 1.12--1.56; Ser/Cys vs. Cys/Cys: OR = 1.19, 95% CI = 1.04--1.37) and recessive model (OR = 1.23, 95% CI = 1.08--1.40), but not with cancers of the SCC, SCLC and LCC ([Table 3](#pone-0035970-t003){ref-type="table"}, [Figure 2](#pone-0035970-g002){ref-type="fig"}).

![ORs of lung cancer with definite histological types associated with the *OGG1* Ser/Ser genotype compared with the Cys/Cys genotype.\
For each study, the estimates of OR and its 95% CI are plotted with a box and a horizontal line. ⋄, pooled ORs and its 95% CIs.](pone.0035970.g002){#pone-0035970-g002}
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###### Meta-analysis of the association between *OGG1* Ser326Cys polymorphism and lung cancer risk.

![](pone.0035970.t002){#pone-0035970-t002-2}

  Variables             No. of studies        Homozygous         *P* ~het~ [a](#nt102){ref-type="table-fn"}      Heterozygous      *P* ~het~ [a](#nt102){ref-type="table-fn"}         Recessive         *P* ~het~ [a](#nt102){ref-type="table-fn"}         Dominant          *P* ~het~ [a](#nt102){ref-type="table-fn"}
  -------------------- ---------------- ----------------------- -------------------------------------------- -------------------- -------------------------------------------- ----------------------- -------------------------------------------- ----------------------- --------------------------------------------
  All                         27           1.15 (0.98--1.36)                       0.001                      1.09 (0.95--1.25)                      0.010                        1.11 (0.97--1.28)                       0.002                        1.09 (0.98--1.21)                      \<0.001
  Cancer type                                                                                                                                                                                                                                                               
  NSCLC                       8            1.29 (0.99--1.69)                       0.118                      1.14 (0.85--1.55)                      0.054                        1.18 (0.90--1.54)                       0.029                        1.20 (0.99--1.45)                       0.125
  Mixed                       19           1.09 (0.89--1.34)                       0.002                      1.08 (0.92--1.26)                      0.016                        1.09 (0.92--1.29)                       0.006                        1.05 (0.93--1.19)                       0.001
  Ethnicity                                                                                                                                                                                                                                                                 
  Caucasian                   11           1.12 (0.78--1.62)                       0.014                      1.08 (0.79--1.47)                      0.107                        1.11 (0.79--1.55)                       0.028                        1.05 (0.88--1.25)                       0.001
  Asian                       12           1.15 (0.92--1.43)                       0.004                      1.04 (0.89--1.22)                      0.030                        1.07 (0.91--1.27)                       0.007                        1.15 (0.98--1.35)                       0.018
  African                     2            1.00 (0.54--1.84)                       0.802                      0.98 (0.53--1.82)                      0.423                        1.01 (0.56--1.83)                       0.653                        1.12 (0.82--1.52)                       0.279
  Mixed                       2            1.48 (0.96--2.27)                       0.224                      1.73 (1.23--2.43)                      0.368                      **1.61 (1.14--2.28)**                     0.284                        1.01 (0.79--1.29)                       0.334
  Source of controls                                                                                                                                                                                                                                                        
  Population                  12           1.15 (0.94--1.40)                       0.335                      1.09 (0.88--1.36)                      0.221                        1.14 (0.94--1.38)                       0.273                        1.08 (0.97--1.19)                       0.617
  Hospital                    15           1.20 (0.94--1.54)                      \<0.001                     1.11 (0.92--1.33)                      0.005                        1.13 (0.93--1.38)                      \<0.001                       1.10 (0.93--1.31)                      \<0.001
  Sample size                                                                                                                                                                                                                                                               
  \<100                       3           4.46 (0.29--68.84)                       0.021                      3.88 (0.41--36.47)                     0.059                       4.33 (0.33--57.22)                       0.024                      **1.79 (1.08--2.98)**                     0.302
  100--500                    19           1.05 (0.83--1.34)                       0.002                      1.01 (0.82--1.25)                      0.010                        1.04 (0.84--1.29)                       0.002                        1.04 (0.91--1.19)                       0.002
  \>500                       5          **1.29 (1.13--1.48)**                     0.920                      1.05 (0.81--1.37)                      0.842                      **1.19 (1.07--1.32)**                     0.953                        1.12 (0.96--1.31)                       0.046

*P* value of the Q-test for heterogeneity test.

10.1371/journal.pone.0035970.t003

###### Meta-analysis of the association between *OGG1* Ser326Cys polymorphism and lung cancer with definite histological types.

![](pone.0035970.t003){#pone-0035970-t003-3}

  Variables             No. of studies        Homozygous         *P* ~het~ [a](#nt104){ref-type="table-fn"}       Heterozygous        *P* ~het~ [a](#nt104){ref-type="table-fn"}         Recessive         *P* ~het~ [a](#nt104){ref-type="table-fn"}       Dominant        *P* ~het~ [a](#nt104){ref-type="table-fn"}
  -------------------- ---------------- ----------------------- -------------------------------------------- ----------------------- -------------------------------------------- ----------------------- -------------------------------------------- ------------------- --------------------------------------------
  Histological types                                                                                                                                                                                                                                                       
  SCLC                        6            0.90 (0.57--1.42)                       0.149                        0.98 (0.67--1.44)                       0.696                        0.97 (0.68--1.39)                       0.357                      1.07 (0.67--1.72)                     0.014
  SCC                         7            1.14 (0.91--1.42)                       0.306                        1.16 (0.96--1.41)                       0.163                        1.14 (0.95--1.38)                       0.143                      1.04 (0.84--1.28)                     0.101
  ADC                         10         **1.32 (1.12--1.56)**                     0.233                      **1.19 (1.04--1.37)**                     0.186                      **1.23 (1.08--1.40)**                     0.248                      1.13 (0.93--1.38)                     0.014
  LCC                         1           3.19 (0.63--16.03)                         \-                        2.18 (0.41--11.69)                         \-                        2.85 (0.58--14.03)                         \-                       1.61 (0.76--3.42)                       \-
  NSCLC                       6          **1.34 (1.03--1.75)**                     0.065                        1.11 (0.89--1.39)                       0.155                        1.18 (0.95--1.46)                       0.086                      1.25 (0.97--1.61)                     0.147
  Mixed                       12         **1.24 (1.02--1.49)**                     0.364                        1.20 (1.00--1.43)                       0.320                      **1.24 (1.05--1.46)**                     0.307                      1.08 (0.96--1.22)                     0.371

SCLC, Small cell lung cancer; SCC, Squamous Cell Carcinoma; ADC, Adenocarcinoma; LCC, Large cell carcinoma; NSCLC, non-small cell lung cancer.

*P* value of the Q-test for heterogeneity test.

The mRNA expression by genotypes {#s3c}
--------------------------------

The mRNA expression level of *OGG1* by the genotypes of four ethnicities is shown in [Table 4](#pone-0035970-t004){ref-type="table"}. We did not find any mRNA expression difference between different genotypes among the four different ethnicities. Thus, mRNA expression level was a little higher though no significant difference for rs1052133G variant allele was found in Asian populations. No trend of transcript expression levels by genotypes was found for *OGG1*.

10.1371/journal.pone.0035970.t004

###### *OGG1* mRNA expression by the genotypes of SNPs, using data from the HapMap[a](#nt105){ref-type="table-fn"}.

![](pone.0035970.t004){#pone-0035970-t004-4}

  Population                                    Genotypes   No.   Mean ± SD   *P* [b](#nt106){ref-type="table-fn"}   *P* ~trend~ [c](#nt107){ref-type="table-fn"}
  -------------------------------------------- ----------- ----- ----------- -------------------------------------- ----------------------------------------------
  **CHB**                                          CC       11    7.84±0.20                                                             0.267
                                                   CG       23    7.94±0.26                  0.280                  
                                                   GG       11    7.96±0.29                  0.264                  
                                                  CG/GG     34    7.95±0.26                  0.234                  
  **JPT** [d](#nt108){ref-type="table-fn"}         CC        8    7.67±0.18                                                             0.125
                                                   CG       26    7.80±0.18                  0.084                  
                                                   GG       10    7.81±0.16                  0.102                  
                                                  CG/GG     36    7.80±0.17                  0.057                  
  **CEU** [d](#nt108){ref-type="table-fn"}         CC       55    7.87±0.31                                                             0.283
                                                   CG       26    7.89±0.28                  0.781                  
                                                   GG        6    7.63±0.18                  0.082                  
                                                  CG/GG     32    7.84±0.28                  0.689                  
  **YRI** [d](#nt108){ref-type="table-fn"}         CC       65    7.80±0.23                                                             0.753
                                                   CG       20    7.77±0.20                  0.568                  
                                                   GG        3    7.83±0.20                  0.869                  
                                                  CG/GG     23    7.78±0.19                  0.637                  
  **Asian** [d](#nt108){ref-type="table-fn"}       CC       19    7.77±0.21                                                             0.106
                                                   CG       49    7.86±0.23                  0.117                  
                                                   GG       21    7.89±0.24                  0.102                  
                                                  CG/GG     70    7.87±0.23                  0.083                  
  **All** [d](#nt108){ref-type="table-fn"}         CC       139   7.82±0.26                                                             0.620
                                                   CG       95    7.85±0.24                  0.420                  
                                                   GG       30    7.83±0.24                  0.883                  
                                                  CG/GG     125   7.85±0.24                  0.468                  

Genotyping data and mRNA expression levels for *OGG1* Ser326Cys by genotypes obtained from the HapMap phase II release 23 data from EBV-transformed lymphoblastoid cell lines from 270 individuals. CHB: 45 unrelated Han Chinese in Beijing; JPT: 45 unrelated Japanese in Tokyo; CEU: 90 Utah residents with ancestry from northern and western Europe; YRI: 90 Yoruba in Ibadan, Nigeria.

Two-side Student\'s *t* test within the stratum.

*P* values for the trend test of *OGG1* mRNA expression among 3 genotypes for each SNP from a general linear model.

There were missing data because genotyping data were not available.

Publication bias {#s3d}
----------------

No publication bias was detected for *OGG1* Ser326Cys (the Egger\'s test, Ser/Ser vs. Cys/Cys: *P* = 0.944, Ser/Cys vs. Cys/Cys: *P* = 0.987, recessive model: *P* = 0.892, dominant model: *P* = 0.217).

Discussion {#s4}
==========

It is well recognized that individual susceptibility to cancer varies, even after exposure to the same environment. Therefore, it has been suggested that genetic variation, such as SNPs of genes is involved in carcinogenesis. We conducted a meta-analysis of published studies to evaluate the association between the *OGG1* Ser326Cys polymorphism and lung cancer risk because no such up-to-date meta-analysis including histological types has been published to date. We found no statistical evidence of an overall effect of the Ser326Cys polymorphism on lung cancer risk in either recessive or dominant effect models. Compared with the Ser/Ser genotype, the variant Cys/Cys genotype was not significantly associated with overall lung cancer risk in all subjects from 27 eligible studies included in the analysis. In a previous meta-analysis with 17 studies consist of 6375 cases and 6406 controls, significantly increased risks were found among Asian subjects in a dominant model, and lung cancer risk associated with the *OGG1* Cys/Cys genotype was significantly increased in population-based studies [@pone.0035970-Li1]. However, these were not found in ours, may be attributed to a larger sample size.

Previous studies demonstrated that genetic variation in *OGG1* affects cancer susceptibility; the frequency of the *OGG1* 326Cys allele was found to be significantly higher in patients when compared with controls [@pone.0035970-Chang2], [@pone.0035970-Janik1], [@pone.0035970-Kohno1], [@pone.0035970-LeMarchand1], [@pone.0035970-Park1]; however, this association was not replicated by other studies [@pone.0035970-Li1], [@pone.0035970-Karahalil2]--[@pone.0035970-Qian1]. Overall, we did not found that individuals carrying the Cys/Cys genotype had significantly increased risk of lung cancer when compared with the Ser/Ser genotype, no significant association with lung cancer risk was found in dominant model, recessive model and heterozygous co-dominant model (Ser/Cys vs. Cys/Cys). However, markedly increased risks were found in relatively large sample size, and this hinted us that in the future studies, only the studies with large sample size would be reliable. In the histological type subgroup analysis, the *OGG1* Ser326Cys allele was significantly associated with risk of ADC, but not with cancers of the SCC, SCLC and LCC. These may be attributed to the tumor specificity.

Mambo et al. [@pone.0035970-Mambo1] analyzed the expression of *hOGG1* mRNA in 18 lung cancer and three normal cell lines and found *hOGG1* was over expressed in most cell lines, 2/18 (11.1%) showed a lower *hOGG1* mRNA and protein expression (∼80% decrease) relative to normal cell lines, indicating 8-Hydroxyguanine repair defects in certain lung cancers. When we compared the mRNA expression levels of *OGG1* Ser326Cys by the genotypes of four different ethnicities, no difference or trend was found. Lung cancer is known to be a complex and multifactorial disease, gene-gene and gene-environment interactions both contribute greatly to the occurrence of this disease, a single nucleotide variation may be insufficient to alter the *OGG1* mRNA expression especially the ones in the coding regions which just lead to amino acid alteration.

Though we included the latest data, there are several limitations in this meta-analysis must also be considered. First, lack of the original data of lung cancer histological types limited our further evaluation of histological types and genotypes interactions. Second, lack of the original data limited our further evaluation of potential gene-gene and gene-environment interactions. Third, lack of information on disease status, genotypes, and well-documented smoking status may also influence the results. Fourth, most of the studies except for five [@pone.0035970-Qian1], [@pone.0035970-Okasaka1], [@pone.0035970-Chang2], [@pone.0035970-Hung1], [@pone.0035970-Kohno2] had a relatively small sample sizes (\<500 cases and controls). Finally, the studies included in the analysis have used more than ten different genotyping methods that had different quality control issues.

In conclusion, this meta-analysis found that the *OGG1* 326Cys/Cys genotype was not associated with significantly increased risk of lung cancer. However, given the relatively limited lung cancer histological types and sample size, Cys/Cys was associated with adenocarcinoma risk. However, further studies are warranted to validate the association between the *OGG1* Ser326Cys polymorphism and lung cancer risk with larger sample size and more detailed histological types.
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